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ABSTRACT
Recombinant receptor cell lines are widely used in G-protein-
coupled receptor selectivity studies. To unequivocally interpret
the results of such studies, it is essential that the host cell line
does not endogenously express the receptor of interest and in
addition is unresponsive to the receptor’s natural ligand. Here
we describe an approach to overcome such difficulties asso-
ciated with orphan receptors or, as in the present case, recep-
tors whose endogenous ligand ubiquitously affects mammalian
cells. The functional heterologous assay system described is
for the hEdg2 receptor, which uses lysophosphatidic acid as its
endogenous ligand. Once activated, this receptor mediates its
effects via multiple secondary messenger pathways, including
a Gi-coupled pathway. We have transiently expressed a per-
tussis toxin-insensitive hEdg2 receptor-ratGia1 fusion protein
into human embryonic kidney cells and have monitored the
ability of compounds to stimulate [35S]GTPgS binding in mem-
branes prepared from these cells after pretreatment with toxin.
Because the assay conditions used favor Gi-mediated re-
sponses and because endogenous Gia subunits are rendered
inactive, the response measured is, by definition, fusion pro-
tein-mediated. Consequently, we have developed an assay that
monitors definitively Edg2 receptor-mediated responses in a
mammalian cell line. A limited structure activity relationship
study suggests that the lysophospholipid carbon chain has a
role in receptor activation and in addition indicates that certain
modifications to the phosphate group are tolerated.
The use of recombinant receptor cells lines is an estab-
lished approach in the search for selective compounds for
G-protein-coupled receptors (GPCRs). Indeed, since the ad-
vent of molecular cloning and the consequent discovery of an
unexpected degree of receptor multiplicity within GPCR su-
perfamilies (e.g., 5-hydroxytryptamine [5-HT]) combined
with subtype colocalization within tissue types it is hard to
imagine how selective compounds could be identified without
such techniques. Great care, however, must be taken in the
choice of host cell lines for such heterologous receptor expres-
sion systems. For example, it is essential that the receptor
subtype under investigation is not endogenously expressed
by the host cell line. To measure the assay endpoint with
confidence, it is necessary to ensure that the host cell is
completely unresponsive to the transfected receptor’s endog-
enous ligand or closely related analogs. Generally this might,
at worst, severely restrict the availability of suitable host cell
types requiring perhaps the use of a less than ideal cell line
in terms of, for example, growth characteristics. In the case of
orphan receptors, i.e., receptors with no known endogenous
ligand, or, as is the case in the present study, receptors whose
endogenous ligand ubiquitously affects mammalian cells,
such considerations become more problematic. Here we de-
scribe an approach to develop a functional assay for the
human Edg2 (hEdg2) receptor that uses lysophosphatidic
acid (LPA) as its endogenous ligand. Evidence is emerging to
suggest that Edg2 receptors play a crucial role in nerve cell
myelination and might offer a potential target in the treat-
ment of demyelinating diseases such as multiple sclerosis.
For example not only are Edg2 receptors expressed exclu-
sively in adult oligodendrocytes and Schwann cells (Weiner
et al., 1998) but also LPA protects against apoptosis in cul-
tured Schwann cells (Weiner and Chun, 1999).
The Edg2 receptor belongs to a GPCR family so called
because the first family member to be cloned was encoded by
an endothelial differentiation gene (Hla and Maciag, 1990).
Eight family members have been identified sharing closest
resemblance to the cannabinoid receptor family. They play
an important role in cell growth, development, and mainte-
nance and in modulating cytoskeletal-dependent changes.
These effects are achieved by activating multiple secondary
messenger pathways involving coupling to numerous tri-
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meric guanine nucleotide-binding proteins (Gi, Gq/11, G12/
13) and/or the small G-protein Rho (Goetzl and An, 1998).
LPA, the endogenous ligand for the Edg2 receptor, is the
simplest of all glycerophospholipids and one of a growing list
of lipid extracellular messengers. It is found in 0.5 mM con-
centrations in serum being formed either by de novo synthe-
sis from glucose-derived dihydroxyacetone phosphate and a
fatty acid-coenzyme A but more probably by enzymatic con-
version of precursor glycerophospholipids (Goetzl and An,
1998). It is largely associated with, and released from, acti-
vated platelets and mediates its effects, at least in part, by
Edg2, Edg4, and Edg7 receptor stimulation.
The ubiquitous responsiveness of mammalian cells lines to
LPA has led not only to a limited choice of suitable host cell
lines for recombinant receptor cell line studies but also to
difficulties in identifying it as the Edg2 receptor endogenous
ligand. Erickson et al. (1998) sought to overcome this prob-
lem by transfecting the hEdg2 receptor in Saccharomyces
cerevisiae and monitoring the activation of the pheromone-
inducible mitogen-activated protein kinase cascade. The
main disadvantage of this approach is the very weak potency
of compounds tested, presumably due to inefficient coupling
of the mammalian receptor with the yeast G-protein, limiting
potential structure activity relationship studies.
An alternative approach described in this study and based
on the Edg2 receptor/Gi signaling pathway has been to con-
struct a fusion protein in which the N terminus of the rGia1
subunit is linked, in-frame, to the C terminus of the Edg2
receptor (Bertin et al., 1994; Stables et al., 1997; Wise et al.,
1997a,b). In addition, the rGia1 subunit has been rendered
pertussis toxin (PTX)-insensitive by the mutation of cysteine
351 to glycine (Milligan, 1988). An agonist-induced
[35S]guanosine 59[g-thio] triphosphate ([35S]GTPgS) binding
assay with membranes from HEK cells transiently express-
ing the hEdg2 receptor-rGia1 fusion protein has then been
developed (Stanton and Beer, 1997). Pretreating the cells
with PTX ensures that the agonist-induced [35S]GTPgS bind-
ing is, by definition, mediated by the transfected receptor.
This fusion protein approach has enabled us to confirm that
LPA activates hEdg2 receptors in mammalian cells. This
assay gives a measure of potency and efficacy and is amena-
ble to high throughput application. Identification of com-
pounds with a range of intrinsic efficacies should be invalu-
able in exploring the physiological/pathophysiological role of
the Edg2 receptor.
Experimental Procedures
Materials. [35S]GTPgS (.1000 Ci/mmol) was obtained from Am-
ersham Pharmacia Biotech (UK). All tissue culture reagents were
from Sigma (St. Louis, MO) or Life Technologies Inc. (Rockville, MD).
PTX and sphingosine-1-phosphate (S-1-P) were purchased from
Sigma and oleoyl 1-acyl-2-hydroxy-sn-glycero-3-phosphate, sodium
salt (LPA), oleoyl (and palmitoyl) 1-acyl-2-hydroxy-sn-glycero-3-
phosphoethanolamine (LPE), oleoyl 1-acyl-2-hydroxy-sn-glycero-3-
[phospho-rac-(1-glycerol)], sodium salt (LPG), and oleoyl 1-acyl-2-
hydroxy-sn-glycero-3-phosphocholine (LPC) were from Avanti Polar
Lipids Inc. (Alabaster, AL). Primers were purchased from Life Tech-
nologies Inc. and restriction enzymes from New England BioLabs
Inc. (Beverly, MA).
Cloning of hEdg2 Receptor. The cDNA encoding the hEdg2
receptor was cloned with polymerase chain reaction (PCR) tech-
niques with a klenTaq polymerase mix (Advantage cDNA PCR kit
from Clontech, Palo Alto, CA). PCR reactions were performed on
human substantia nigra cDNA (Clontech) with the primers 59-GT-
CATGGCTGCCATCTCTACT-39 (sense) and 59-GTTCTAAACCACA-
GAGTGGTC-39 (antisense). The PCR-amplified fragment was sub-
cloned into pCR-Blunt II-TOPO (Invitrogen, Carlsbad, CA) and
confirmed as that encoding for the hEdg2 receptor by sequencing.
For use in the cotransfection studies the hEdg2 receptor cDNA was
excised with the restriction enzymes XhoI and HindIII and ligated
into the mammalian expression vector pcDNA3.1(2) (Invitrogen).
For the hEdg2 receptor-Cys351 3 Gly rGia1 fusion studies the open
reading frame (ORF) of the hEdg2 receptor underwent further PCR
with the following primers containing HindIII and NcoI restriction
sites, respectively (underlined), 59-AAGCTTATGGCTGCCATCTC-
TACTTCCATC-39 (sense) and 59-CCATGGCAACCACAGAGTGGT-
CATTGCTGT-39 (antisense). The PCR-amplified fragment was then
subcloned into pCRII-TOPO (Invitrogen).
Construction of Cys3513Gly rGia1. Site-directed mutagenesis
on the rGia1 subunit [with a QuikChange kit (Stratagene, La Jolla,
CA)], was carried out to remove a NcoI site (Ala87, GCC3GCG)
within the ORF. This allowed a NcoI site at the beginning of the ORF
to be used as the site of fusion of the hEdg2 receptor to the rGia1
subunit. To render the rGia1 subunit PTX-insensitive, the cDNA
underwent PCR with the Advantage cDNA PCR kit and the pri-
mers 59-GAATTCCCATGGGCTGCACACTGAGCGCTGAGGACA-39
(sense) and 59-GCGGCCGCTCTAGATTAGAAGAGACCACCGTC-
TTTTAGGTTATT-39 (antisense) (Cys351 3 Gly in bold; restriction
sites for EcoRI, Nco 1, NotI, and XbaI underlined) resulting in a
Cys3513 Gly mutation in the 39 end of the rGia1 subunit and hence
to PTX insensitivity. This PCR product was then reinserted into the
EcoRI/XbaI site of pBluescript SK(2), and the mutation was con-
firmed by sequence analysis.
Construction of the hEdg2 Receptor-Cys351 3 Gly rGia1
Fusion Protein. The hEdg2 cDNA in pCRII-TOPO was digested
with HindIII and NcoI and ligated into the Cys351 3 Gly rGia1
subunit containing pBluescript SK(2), itself having been digested
with HindIII and NcoI. Introduction of the NcoI site at the 39 end of
the ORF of the receptor resulted in the removal of the stop codon and
insertion of an extra alanine between the receptor and rGia1 sub-
unit. The full fusion construct was then excised from pBluescript
SK(2) with HindIII and NotI, ligated into the mammalian expres-
sion vector pcDNA3.1(1) and confirmed by sequence analysis.
Construction of the myc and Hemaglutinin (HA) Epitope-
Tagged rGia1 Subunits. The myc (EQKLISEED) and HA (DVP-
DYA) epitope tags were engineered into the rGia1 subunit after the
sixth amino acid residue from its N terminus. The 59-oligonucleotides
containing the myc and HA tags (underlined) and an EcoRI (GAA
TTC) restriction site were ATC GAA TTC ATG GGC TGC ACA CTG
AGC GCT GAG CAG AAG CTG ATC TCC GAG GAG GAC CTG GAG
GAC AAG GCG GCC GTG GAG and ATC GAA TTC ATG GGC TGC
ACA CTG AGC GCT GAC GTC CCC GAC TAC GCG GAG GAC AAG
GCG GCC GTG GAG, respectively. The 39-oligonucleotide containing
the stop codon and an XbaI restriction site (ATC TAG) was AT ATC
TAG ACT AGC AGA GCT TAG AAG AGA CCA CAG TCT. Introduc-
tion of the epitope tags was achieved with standard PCR methodol-
ogies. The PCR products were then restriction enzyme-digested and
subcloned into pcDNA3.1(1). The sequence of these constructs was
confirmed by an ABI 375 automated fluorescence sequencer.
Transient Transfection of Human Embryonic Kidney
(HEK) 293 Cells. HEK cells were plated out at a density of 3 3 105
cells/ml in cell culture dishes containing 10 ml of Dulbecco’s modified
Eagle’s medium (with 8% fetal calf serum) and incubated overnight.
The following day 0.5 ml of 0.25 M CaCl2, 0.5 ml 23 BBS buffer (50
mM N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid, 280 mM
NaCl, 1.5 mM Na2HPO4), pH 6.95, and DNA (7.5 mg of hEdg2
receptor plus 7.5 mg of rGia1 subunit [tagged, wild type, or Cys3513
Gly-mutated] for cotransfection studies and 15 mg for the hEdg2
receptor-rGia1 fusion protein) was made up, left at room tempera-
ture (RT) for 15 min, and added to each cell culture dish. The HEK
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cells were incubated at 37°C in 3% CO2 for 48 to 60 h before being
harvested in phosphate-buffered saline and stored at 270°C. For the
PTX studies 100 ng/ml PTX was added to the cell medium 20 h before
harvesting.
Agonist-Induced [35S]GTPgS Binding. Untransfected HEK
293, CHO-K1, Ltk2, HeLa, COS-7, PC12, or HEK 293 cells tran-
siently expressing the hEdg2 receptor either alone or cotransfected
with the rGia1 subunit (HA or myc epitope tagged at the N terminus
of the subunit, wild type, or Cys3513Gly-mutated) were homoge-
nized in ice-cold 20 mM HEPES buffer containing 10 mM EDTA (pH
7.4 at RT) with a Kinematica polytron (setting 5, 10 s) and centri-
fuged at 48,000g, 4°C for 15 min. The pellet was resuspended in
ice-cold 20 mM HEPES buffer containing 0.1 mM EDTA (pH 7.4 at
RT) and recentrifuged at 48,000g, 4°C for 15 min. The final pellet
was resuspended in 20 mM HEPES buffer containing 100 mM NaCl
and 10 mM MgCl2, pH 7.4, at RT.
Membranes (2.5 mg wet weight) were incubated with GDP (1 mM)
and diluted with test drug in assay buffer containing 1% fatty acid
free BSA (final assay concentration of 0.1% BSA) for 20 min at 30°C
before being placed on ice for 15 min. [35S]GTPgS (100 pM) was then
added to a final volume of 1 ml, and the tubes were incubated for a
further 30 min at 30°C. The incubation was terminated by filtering
over GF/B filters with a cell harvester (Brandel Research and Devel-
opment Laboratories, Inc., Gaithersburg, MD), and the filters were
washed once with 5 ml of water. Radioactivity was counted by liquid
scintillation spectrometry at an efficiency of .90%.
Data Analysis. Background filter counts, i.e., residual radioac-
tivity bound to the filter in the absence of membrane, were sub-
tracted from each sample count. Test results are represented as
either percentage increase in binding above basal (that seen in the
absence of test compound) or stimulated 2 basal dpm. Dose-response
curves were plotted and analyzed by nonlinear, least-squares regres-
sion analysis with an iterative curve-fitting routine (Marquardt-
Levenberg method) provided by the data manipulation software RS/1
(Software Products Corp., Cambridge, MA). Potency values are ex-
pressed as pEC50 values (2log10 concentration of agonist required to
give 50% of its own maximal stimulation). Efficacy values are given
as a percentage of the maximal response seen with LPA. Data are
expressed as arithmetic mean 6 S.E. from $3 experiments.
Results
All assays were carried out in the presence of 1 mM GDP.
Addition of GDP favors binding to Gia subunits, which have
a relatively high spontaneous rate of GDP dissociation. As
expected, LPA dose dependently increased [35S]GTPgS bind-
ing in all the nontransfected cell lines tested with varying
degrees of efficacy (Fig. 1), and as anticipated this response
was abolished after pretreatment of membranes (HEK cells)
with PTX (100 ng/ml) due to ADP-ribosylation of endogenous
Gi/o-proteins (data not shown). The following rank order of
responsiveness was seen: Ltk2 5 CHO .. PC12 . HeLa 5
HEK 5 COS-7. HEK cells were used for all subsequent
transient expression studies, because they displayed a rela-
tively low endogenous LPA response and were known to have
good transfection efficiency.
The LPA-mediated [35S]GTPgS binding in the hEdg2 re-
ceptor-expressing cell line, either alone or together with the
various Gi constructs or as a PTX-insensitive hEdg2 recep-
tor-rGia1 fusion protein, is shown in Fig. 2. The maximal
response to LPA after transient transfection of the hEdg2
receptor alone was only modestly improved compared with
that seen in the mock or untransfected cells (10%). The
response was improved by cotransfection of the receptor with
the wild-type rat Gia1 (rGia1) subunit (25 6 1%), was further
enhanced when the wild-type rGia1 subunit was replaced
with HA (27 6 2%) or myc (30 6 5%) N-terminal-tagged
rGia1 subunits and even more so when replaced with the
mutant rGia1 subunit (48 6 3%). The transient expression of
the PTX-insensitive hEdg2 receptor-rGia1 fusion protein
yielded the most efficacious response (69 6 10%). The po-
tency values of LPA, under the various assay conditions, are
presented in Table 1 as pEC50 values.
In a second series of experiments, the effects of PTX pre-
treatment (100 ng/ml) on the hEdg2 receptor-expressing cells
cotransfected with the various Gi constructs or as a PTX-
insensitive hEdg2 receptor-rGia1 fusion protein were inves-
tigated (Fig. 3). Compared with the equivalent untreated
cells, PTX treatment led to a dramatic reduction in the mea-
surable LPA-mediated response seen in the rGia1HA(N) sub-
unit and the rGia1 myc(N) subunit cotransfected cell lines
(77 6 8% and 73 6 5%, respectively) and abolished the
response in the wild-type rGia1 subunit-cotransfected cell
line. In contrast, PTX pretreatment of the cells transiently
transfected with the hEdg2 receptor-rGia1 fusion protein
Fig. 1. LPA-induced [35S]GTPgS binding, in the presence of 1 mM GDP,
mediated by endogenous receptors in HEK 293 (f), CHO-K1 (Œ), Ltk2
(), HeLa (l), COS-7 (M), and PC12 (E) cells. Data are expressed as
percentage increase in binding above basal. Curves are a composite of
three or more separate experiments, mean 6 S.E.
Fig. 2. LPA-induced [35S]GTPgS binding, in the presence of 1 mM GDP,
mediated by mock (E), hEdg2 receptor (f), hEdg2 receptor 1 wild-type
rGia1 subunit (Œ), hEdg2 receptor 1 rGia1HA(N) subunit (), hEdg2
receptor 1 rGia1 myc(N) subunit (l), hEdg2 receptor 1 mutant rGia1
subunit (‚), and the hEdg2 receptor-rGia1 fusion protein (F) transiently
transfected HEK cells. For potency (pEC50) and efficacy (Emax) values see
Table 1. Data are expressed as percentage increase in binding above
basal. Each curve is a composite of four experiments, mean 6 S.E.
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was without effect on either the efficacy or potency values
generated.
The potency and efficacy values (with respect to LPA) for
several lysophospholipids in the PTX-pretreated hEdg2 re-
ceptor-rGia1 fusion protein-expressing HEK cells are given
in Table 2. LPA was, by over an order of magnitude, the most
potent compound tested. LPG was marginally less effica-
cious. LPE (oleoyl) and S-1-P were able to induce hEdg2
receptor-mediated [35S]GTPgS binding albeit with much re-
duced potency and efficacy. LPC (oleoyl) and LPE (palmitoyl)
were inactive at up to 100 and 30 mM concentrations, respec-
tively.
Discussion
Edg receptors are classified into two subfamilies, depend-
ing on their amino acid sequence similarity (within a sub-
group, 44–52%; between subgroups, 27–34%) and their pre-
ferred endogenous ligand. Edg1, -3, -5, and -8 receptors are
activated by S-1-P and Edg2, -4, and -7 receptors by LPA. The
orphan Edg6 receptor displays a 30 to 40% amino acid iden-
tity with both subgroups. These receptors lack the commonly
seen disulfide bridge between extracellular loops 1 and 2,
which might be relevant in providing a suitable binding
pocket for the bulky ligand.
Members of this family activate multiple secondary mes-
senger pathways (Gi, Gq/11, G12/13, and/or Rho coupled).
The effector system(s) activated could conceivably depend on
the receptor subtype, the ligand concentration, and, there-
fore, the level of receptor activation as well as the internal
milieu of the host cell type in both native tissue and recom-
binant receptor cell lines.
Edg receptors are expressed in most mammalian cells,
with each subtype having a distinct distribution pattern,
raising the possibility of tissue-specific biological roles that
could be explored in drug discovery programs. Several sub-
types are often expressed within the same tissue and possibly
on differing cells types. Expression on the same cell may
allow subtle control mechanisms that increase the repertoire
of endogenous ligands, perhaps involving synergism between
phospholipids.
Exploration of the physiological/pathophysiological roles of
these receptors requires the identification of selective com-
pounds, preferably with a range of intrinsic efficacies. Here
we describe an assay that allows efficient profiling of com-
pounds at the hEdg2 receptor.
The complex intracellular pathways activated by Edg re-
ceptors offer several potential biochemical markers of recep-
tor activation. However, monitoring an early event in the
signaling cascade should increase the probability of develop-
ing an assay design, which could be applied to all Edg recep-
tors, rather than an assay based on a more downstream
signaling event, when divergence between receptor subtypes
is more likely to have occurred. Agonist-induced [35S]GTPgS
binding, employing recombinant receptor cell lines, is an
established in vitro functional assay for GPCRs and fulfills
TABLE 1
Basal constitutive activity and LPA-induced [35S]GTPgS binding
following transient transfections
Levels of basal activity, i.e., in the absence of agonist, seen in membranes prepared
from HEK cells transiently transfected with the hEdg2 receptor (alone or together
with the various Gi constructs) or the hEdg2 receptor-rGia1 fusion protein or
mock-transfected HEK cells are presented as dpm bound. Potency values for LPA-
induced [35S]GTPgS binding carried out in membranes prepared from each condition
are given as pEC50 values, and efficacy values (Emax) are the maximal stimulation
achieved. Results are arithmetic means 6 S.E. of four experiments.
Basal 6 S.E. pEC50 6 S.E. Emax 6 S.E.
dpm %
hEdg2 20,099 6 1,931 8.3a 10a
hEdg2 1 wild-type rGia1 25,037 6 3,984 8.0 6 0.2 25 6 1
hEdg2 1 rGia1HA(N) 23,279 6 2,085 7.7 6 0.1 27 6 2
hEdg2 1 rGia1myc(N) 30,557 6 4,352 7.6 6 0.1 30 6 5
hEdg2 1 mutant rGia 19,986 6 1,851 7.6 6 0.1 48 6 3
hEdg2-rGia1 fusion 22,693 6 2,506 7.3 6 0.1 69 6 10
No DNA 12,472 6 720 NA NA
a Only two determinations were made.
Fig. 3. LPA-induced [35S]GTPgS binding medi-
ated, in the presence of 1 mM GDP, by (A) hEdg2
receptor 1 rGia1HA(N) subunit, (B) hEdg2 re-
ceptor 1 rGia1 myc(N) subunit, (C) hEdg2 recep-
tor 1 wild-type rGia1 subunit, and (D) hEdg2
receptor-rGia1 fusion protein transiently trans-
fected HEK cells, in the absence (F) or presence
() of 100 ng/ml PTX. Data are expressed as
stimulated 2 basal dpm. Each curve is a compos-
ite of three or more experiments, mean 6 S.E.
PTX treatment completely abolished the mea-
surable LPA response in the wild-type rGia1 co-
transfected cell line and reduced the response
seen in the rGia1 HA(N) and the rGia1 myc(N)
cotransfected cell lines when compared with the
equivalent untreated cells (77% and 73%, respec-
tively). In contrast, PTX pretreatment of hEdg2
receptor-rGia1 fusion protein-expressing cells
was without effect on either the efficacy or po-
tency values generated.
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this condition. The assay measures the accumulation of the
nonhydrolyzable GTP analog, [35S]GTPgS, which displaces
a-subunit-bound GDP after receptor activation.
The ubiquitous responsiveness of mammalian cells to LPA
restricts the availability of suitable host cell lines, because
responses might be due to endogenous receptor activation.
We therefore took the approach of developing an assay with
a PTX-insensitive hEdg2 receptor-rGia1 fusion protein-ex-
pressing cell line (Bertin et al., 1994; Wise et al., 1997b).
Transient transfection of the hEdg2 receptor into HEK
cells led to a modest increase in the maximal LPA-mediated
response compared with mock-transfected cells. Not unex-
pectedly, an improved stimulation was seen after coexpres-
sion with the wild-type rGia1 subunit. This response was
further enhanced by replacing wild-type rGia1 subunits with
either HA or myc N-epitope tagged rGia1 subunits. These
tags were inserted near the N terminus to minimize possible
interference with the secondary signaling cascade and in
particular with the conformational changes required for
GTPgS acceptance in the a-subunit binding pocket. The sim-
plest explanation for this enhanced response is a more effi-
cient subunit expression. However, because a similar effect
was also seen with the poorly coupled h5-HT5A receptor but
not the efficiently coupled hEdg4 receptor (unpublished
data), it is probably due to improved receptor-subunit cou-
pling.
After ligand activation, GPCRs interact with G-proteins to
promote an a-subunit “open” conformation. The Gia1 subunit
N-terminal region is involved in contact sites with the recep-
tor, the effector binding surface, and the a-bg subunit inter-
face (Wall et al., 1995; Lambright et al., 1996) in addition to
cell membrane anchorage (Wise and Milligan, 1997). Hence,
enhanced efficacy seen with the N-terminal-tagged subunits
might be due to either a direct effect at contact sites involved
in the conformational changes (Kisselev et al., 1995a,b; Tay-
lor et al., 1996) or to improved maneuverability of the sub-
unit at its point of attachment to the cell membrane, i.e.,
opposite to fusion protein compartmentalization effects (see
below). Similar effects on compound efficacy were reported
after a2A-adrenoceptor-Cys
351 3 Gly Gia1 fusion protein
b1g2 coexpression studies and argued to be due to enhanced
bg-subunit interactions allowing more effective transduction
(Wise et al., 1997a; Wise and Milligan, 1997).
The most efficacious LPA responses were seen after mu-
tant rGia1 receptor cotransfection and hEdg2 receptor-rGia1
fusion protein transfection, although the fusion protein gave
a greater response. The direct in-frame fusion of the N ter-
minus of the a-subunit to the C terminus of the receptor was
achieved by substituting the stop codon of the receptor with
alanine and maintaining the a-subunit initiator methionine
(Bertin et al., 1994; Wise et al., 1997a) and the PTX insensi-
tivity by mutation of the a-subunit cysteine 351 to glycine
(Hunt et al., 1994; Wise et al., 1997b). These results suggest
that the enhanced response seen with the fusion protein is, at
least in part, due to the cysteine 351 to glycine mutation.
The LPA response seen after transfection of the fusion
protein was unaffected by pretreatment of the cells with PTX
(Fig. 3D). In contrast, PTX pretreatment in coexpression
studies resulted in a dramatic reduction in the maximal
stimulation (Fig. 3, A–C). The residual activity is possibly
due to interference of the mutation in the efficiency of ADP-
ribosylation.
Published studies (e.g., Sautel and Milligan, 1998), with
a2A-adrenoceptors, indicate that fusion proteins result in
compromised coupling efficiency possibly due to physical re-
strictions inhibiting protein conformational changes or ef-
fects on the compartmentalization of signaling elements
within specific domains of the plasma membrane interfering
with signal transduction (Huang et al., 1997; Sautel and
Milligan, 1998). This study supports these findings, because
the LPA potency with the fusion protein was 5- and 2-fold
weaker than that seen with the wild-type and mutant rGia1
cotransfection studies, respectively.
Finally we have investigated the ability of non-LPA phos-
pholipids to activate the Edg2 receptor. All compounds tested
were shown to have an LPA content of less than 0.2%. We
have demonstrated with this fusion protein that attaching
groups to the phosphate of LPA does not prevent hEdg2
receptor activation. Glycerol and ethanolamine, but not cho-
line, are tolerated albeit with reduced potency and efficacy.
Consistent with the findings of other groups (see below) the
nature of the carbon chain seems to be critical, because 30
mM LPE (palmitoyl; C 16:0) in contrast to LPE (oleoyl; C18:1)
was inactive. Additionally, the study indicates that two acyl
side chains are also tolerated. S-1-P yielded an efficacy of
22% compared with LPA.
Erickson et al. (1998), with a reporter gene assay monitor-
ing the pheromone response pathway in Saccharomyces cer-
evisiae, found LPA (18:1 oleoyl) to have an EC50 of 20 to 30
mM, LPE to be weakly active, and S-1-P to be inactive. These
weak activities probably reflect poor coupling of the mam-
malian receptor to the yeast G-protein and highlight the
increased sensitivity of the approach taken in the present
study. The yeast study also indicates the importance of li-
gand chain length. LPA analogs with increased chain length
were more efficacious, and those with 6 and 10 carbon chains
were inactive.
Consistent with the present study, Fukushima et al. (1998)
report LPA (1 mM) induced [35S]GTPgS binding after tran-
sient transfection of Edg2 receptors into Rh7777 rat hepa-
toma cells and stable transfection into B103 neuroblastoma
cells. LPC, LPE, and LPG (1 mM) were inactive. These ap-
parent discrepant findings might be explained by increased
responsiveness and hence sensitivity of the fusion protein
assay.
Finally, with hEdg2 receptors transiently expressed in
Jurkat cells and a serum response element-driven luciferase
TABLE 2
Potency and efficacy values for LPA and analogs using agonist-induced
[35S]GTPgS binding mediated by the pertussis toxin-insensitive hEdg2
receptor-rGia1 fusion protein
Potency (pEC50) and efficacy values (Emax) for LPA and related phospholipids in the
agonist-induced [35S]GTPgS binding assay were carried out in membranes prepared
from PTX treated (100 ng/ml for 20 h before harvesting) hEdg2 receptor-rGia1 fusion
protein transiently expressing HEK cells. Efficacy values are the maximal stimula-
tion achieved and are presented as a percentage of the maximal LPA response.
Results are arithmetic means 6 S.E. of $3 experiments.
Compound pEC50 6 S.E. Maximal LPA Response
%
LPA (oleoyl C18:1) 6.7 6 0.1 100
LPG (oleoyl C18:1) 5.0 6 0.1 84 6 3
LPE (oleoyl C18:1) 5.0 6 0.2 29 6 2
LPC (oleoyl C18:1) Inactive
LPE (palmitoyl C16:0) Inactive
S-1-P 5.7 6 0.2 22 6 1
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expression reporter gene assay, An et al. (1998) report an
EC50 value of 10 nM for LPA. This assay therefore appears to
have increased sensitivity; however, the authors also report
that the Jurkat cells might express an “as yet unidentified
LPA receptor subtype,” which would prove problematic when
interpreting data from novel structurally diverse Edg recep-
tor mimetics. In addition, S-1-P, LPC, and LPE were inac-
tive, although compounds were tested only at concentrations
up to 1 mM unlike the present study where compounds were
tested up to 30 to 100 mM.
The present study, demonstrating dose-dependent LPA-
induced [35S]GTPgS binding in PTX-pretreated cells express-
ing the PTX-insensitive hEdg2 receptor-rGia1 subunit fusion
protein, clearly indicates that LPA activates this receptor. In
addition to this certainty, the assay has good sensitivity,
measures of compound potency, and efficacy and is amenable
to high throughput application. The limited number of com-
pounds tested indicates that structural modifications to LPA,
in particular attachments to the phosphate group and the
length and number of acyl side chains, are tolerated for Edg2
receptor activation.
GPCR fusion proteins have been used for several applica-
tions, e.g., to elucidate complex interactions between mem-
bers of signaling pathways and the nature of agonist efficacy
under conditions of fixed receptor/G-protein stoichiometry
(Bertin et al., 1994; Wise et al., 1997a,b). Here we demon-
strate a further application that, with the use of appropriate
a-subunits (chimeric or otherwise), toxins, and assays, could
be applied to other GPCRs that have a widespread endoge-
nous expression in mammalian cells, e.g., thrombin, adeno-
sine, UTP, and prostaglandin E receptors. Finally, the ser-
endipitous finding that cotransfection of tagged/mutated
rGia1 subunits enhance the response compared with the
wild-type a-subunit might be applicable to assay develop-
ment for poorly coupled GPCRs.
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